BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 35790854)

  • 1. Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.
    Gao J; Pickett HA
    Nat Rev Cancer; 2022 Sep; 22(9):515-532. PubMed ID: 35790854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomere maintenance mechanisms in cancer: telomerase, ALT or lack thereof.
    Claude E; Decottignies A
    Curr Opin Genet Dev; 2020 Feb; 60():1-8. PubMed ID: 32114293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALT: A Multi-Faceted Phenomenon.
    Sommer A; Royle NJ
    Genes (Basel); 2020 Jan; 11(2):. PubMed ID: 32012790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT).
    De Vitis M; Berardinelli F; Sgura A
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative Lengthening of Telomeres: DNA Repair Pathways Converge.
    Sobinoff AP; Pickett HA
    Trends Genet; 2017 Dec; 33(12):921-932. PubMed ID: 28969871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
    Liu H; Xu C; Diplas BH; Brown A; Strickland LM; Yao H; Ling J; McLendon RE; Keir ST; Ashley DM; He Y; Waitkus MS
    Neuro Oncol; 2023 Sep; 25(9):1563-1575. PubMed ID: 36689342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?
    Akter J; Kamijo T
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone demethylase KDM2A is a selective vulnerability of cancers relying on alternative telomere maintenance.
    Li F; Wang Y; Hwang I; Jang JY; Xu L; Deng Z; Yu EY; Cai Y; Wu C; Han Z; Huang YH; Huang X; Zhang L; Yao J; Lue NF; Lieberman PM; Ying H; Paik J; Zheng H
    Nat Commun; 2023 Mar; 14(1):1756. PubMed ID: 36991019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SLX4IP N-terminus dictates telomeric localization in ALT-like castration-resistant prostate cancer cell lines.
    Mangosh TL; Grabowska MM; Taylor DJ
    Prostate; 2021 Nov; 81(15):1235-1251. PubMed ID: 34492133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative mechanisms of telomere lengthening: permissive mutations, DNA repair proteins and tumorigenic progression.
    Gocha ARS; Harris J; Groden J
    Mutat Res; 2013; 743-744():142-150. PubMed ID: 23219603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The telomere maintenance mechanism spectrum and its dynamics in gliomas.
    Kim S; Chowdhury T; Yu HJ; Kahng JY; Lee CE; Choi SA; Kim KM; Kang H; Lee JH; Lee ST; Won JK; Kim KH; Kim MS; Lee JY; Kim JW; Kim YH; Kim TM; Choi SH; Phi JH; Shin YK; Ku JL; Lee S; Yun H; Lee H; Kim D; Kim K; Hur JK; Park SH; Kim SK; Park CK
    Genome Med; 2022 Aug; 14(1):88. PubMed ID: 35953846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative Lengthening of Telomeres (ALT) in Tumors and Pluripotent Stem Cells.
    Zhao S; Wang F; Liu L
    Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31835618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation mediated up-regulation of TERRA non-coding RNA is coincident with elongated telomeres in the human placenta.
    Novakovic B; Napier CE; Vryer R; Dimitriadis E; Manuelpillai U; Sharkey A; Craig JM; Reddel RR; Saffery R
    Mol Hum Reprod; 2016 Nov; 22(11):791-799. PubMed ID: 27604461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Telomere Recombination in Normal Mammalian Cells].
    Zhdanova NS; Rubtsov NB
    Genetika; 2016 Jan; 52(1):14-23. PubMed ID: 27183789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative lengthening of telomeres: mechanism and the pathogenesis of cancer.
    Mori JO; Keegan J; Flynn RL; Heaphy CM
    J Clin Pathol; 2024 Jan; 77(2):82-86. PubMed ID: 37890990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional Loss of
    Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
    Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Life and cancer without telomerase: ALT and other strategies for making sure ends (don't) meet.
    Apte MS; Cooper JP
    Crit Rev Biochem Mol Biol; 2017 Feb; 52(1):57-73. PubMed ID: 27892716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Molecule Telomere Assay via Optical Mapping (SMTA-OM) Can Potentially Define the ALT Positivity of Cancer.
    Raseley K; Jinwala Z; Zhang D; Xiao M
    Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of the alternative lengthening of telomeres pathway by trapping of proteins on DNA.
    Rose AM; Goncalves T; Cunniffe S; Geiller HEB; Kent T; Shepherd S; Ratnaweera M; O'Sullivan RJ; Gibbons RJ; Clynes D
    Nucleic Acids Res; 2023 Jul; 51(13):6509-6527. PubMed ID: 36940725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative lengthening of telomeres in cancer stem cells in vivo.
    Bojovic B; Booth RE; Jin Y; Zhou X; Crowe DL
    Oncogene; 2015 Jan; 34(5):611-20. PubMed ID: 24531712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.